US-based Co-Diagnostics, Inc., a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, has entered into a definitive agreement with Arabian Eagle Manufacturing, a regional manufacturing and distribution company based in the Kingdom of Saudi Arabia (KSA) to form a joint venture (JV), CoMira Diagnostics, to research, develop, manufacture, assemble, distribute, and commercialise Co-Dx technologies and intellectual property, including the company's upcoming Co-Dx™ PCR point-of-care platform, within KSA and 18 other countries throughout the Middle East and North Africa (MENA).
According to the JV agreement, Arabian Eagle will contribute local operational and customer support, lead the manufacturing facility set-up and regulatory clearance/registration responsibilities, manage other logistics activities and ensure compliance with local industrial and commercial laws in pursuit of the JV's objectives across the Territory.
Similar to the company's partnership in India with its existing JV, CoSara Diagnostics Pvt Ltd, Co-Dx will provide CoMira an exclusive license to use, manufacture, and commercialise the licensed IP, which will include the upcoming Co-Dx PCR platform as well as the company's existing suite of lab-based PCR diagnostic products. Infectious disease tests on the new platform currently in preparation to begin clinical evaluations before the end of 2025 in various jurisdictions include tuberculosis, an 8-type HPV multiplex test, and an upper respiratory multiplex test for influenza A and B, COVID-19, and RSV.
Other MENA countries included in the Territory consist of Bahrain, Iraq, Jordan, Kuwait, Lebanon, Oman, Palestine, Qatar, Syria, Turkey, United Arab Emirates (UAE), Yemen, Algeria, Egypt, Libya, Morocco, Sudan and Tunisia.
